- In July 2022, Incyte Corporation received FDA approval for Opzelura (ruxolitinib) cream 1.50% to treat non-segmental vitiligo, marking it as the first and only FDA-approved product for repigmentation in this condition. The approval was supported by data from the pivotal Phase 3 TRuE-V clinical trial program, demonstrating its efficacy. This milestone has given Incyte a significant competitive advantage in the vitiligo treatment market, allowing for continuous topical use of Opzelura
- In October 2021, Uniza Group introduced Vitellus, an innovative 3-in-1 solution combining Greyverse, Melitane, GL 200, and EUK-134, to the Indian market. Vitellus promotes melanin production, addresses skin pigmentation issues, and enhances hair follicle pigmentation while also functioning as a powerful antioxidant. This launch has enabled Uniza to diversify its product portfolio and solidify its position within the competitive pigmentation treatment market
- In June 2023, Merck, referred to as MSD in markets outside the United States and Canada, completed its acquisition of Prometheus Biosciences, Inc. As a result, Prometheus is now a wholly-owned subsidiary of Merck, and its common stock will no longer be listed or traded on the Nasdaq Global Market. This strategic acquisition enhances Merck's portfolio and strengthens its position in the biotechnology sector
- In May 2023, Sandoz, a leading global provider of off-patent medicines, revealed a multi-year partnership with Just - Evotec Biologics, a subsidiary of Evotec SE based in Seattle. This collaboration aims to leverage both companies' expertise to advance the development of innovative biosimilar therapies. The partnership is expected to enhance Sandoz's offerings in the competitive generic and biosimilar markets
Frequently Asked Questions
The market is segmented based on Segmentation, By Disease Type (Melasma, Vitiligo, Albinism, Post-Inflammatory Hyperpigmentation, and Others), Treatment Type (Pharmacological Treatment, Non-Invasive Treatment, and Surgery), Drugs (Calcineurin Inhibitors, Melanocyte-Stimulating Hormone, and Others), Route of Administration (Oral, Topical, and Others), End-Users (Dermatology Clinics, Aesthetic Clinics, Homecare, Hospitals, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Pigmentation Disorders Treatment Market size was valued at USD 601.87 USD Million in 2023.
The Global Pigmentation Disorders Treatment Market is projected to grow at a CAGR of 7.3% during the forecast period of 2024 to 2031.
The major players operating in the market include Zerigo Health, Bausch Health Companies, Glenmark Pharmaceuticals, Novartis, Pfizer, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, Mylan, Bayer, CLINUVEL PHARMACEUTICALS, yte, Strides Pharma Science, Panacea Biotec, Belcher Pharmaceuticals, LEO Pharma, Astellas Pharma, Episciences, Obagi Cosmeceuticals.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
